Literature DB >> 24849569

The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare?

Richard E Pratley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24849569     DOI： 10.1007/s00125-014-3263-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  3 in total

1.  Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.

Authors:  Bo Ahrén; Chantal Mathieu; Giovanni Bader; Anja Schweizer; James E Foley
Journal:  Diabetologia       Date:  2014-03-29       Impact factor: 10.122

2.  A historical perspective on clinical trials innovation and leadership: where have the academics gone?

Authors:  David L DeMets; Robert M Califf
Journal:  JAMA       Date:  2011-02-16       Impact factor: 56.272

3.  Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).

Authors:  C Mathieu; A H Barnett; H Brath; I Conget; J J de Castro; R Göke; E Márquez Rodriguez; P M Nilsson; E Pagkalos; A Penfornis; N C Schaper; S K Wangnoo; W Kothny; G Bader
Journal:  Int J Clin Pract       Date:  2013-08-21       Impact factor: 2.503
  3 in total
  9 in total

1.  Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus.

Authors:  T Battelino; S Liabat; H J Veeze; J Castañeda; A Arrieta; O Cohen
Journal:  Diabet Med       Date:  2015-07-14       Impact factor: 4.359

2.  Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.

Authors:  You-Cheol Hwang; Ari Kim; Euna Jo; Yeoree Yang; Jae-Hyoung Cho; Byung-Wan Lee
Journal:  BMC Endocr Disord       Date:  2017-10-25       Impact factor: 2.763

Review 3.  Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus.

Authors:  Brian M Frier; Alexandria Ratzki-Leewing; Stewart B Harris
Journal:  Diabetes Obes Metab       Date:  2019-04-29       Impact factor: 6.577

4.  Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.

Authors:  L Meneghini; A Doshi; D Gouet; T Vilsbøll; K Begtrup; P Őrsy; M F Ranthe; I Lingvay
Journal:  Diabet Med       Date:  2019-11-28       Impact factor: 4.359

5.  Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies.

Authors:  S Yu Martsevich; Yu V Lukina; N P Kutishenko; Yu V Semenova
Journal:  Contemp Clin Trials Commun       Date:  2021-02-17

6.  Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.

Authors:  Tracey Weiss; Richard D Carr; Sampriti Pal; Lingfeng Yang; Baanie Sawhney; Robert Boggs; Swapnil Rajpathak; Kristy Iglay
Journal:  Patient Prefer Adherence       Date:  2020-11-27       Impact factor: 2.711

7.  Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study).

Authors:  Sunghwan Suh; Sun Ok Song; Jae Hyeon Kim; Hyungjin Cho; Woo Je Lee; Byung-Wan Lee
Journal:  J Diabetes Res       Date:  2017-08-24       Impact factor: 4.011

8.  Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal.

Authors:  Carla Torre; José Guerreiro; Patrícia Longo; João Filipe Raposo; Hubert Leufkens; Ana Paula Martins
Journal:  Patient Prefer Adherence       Date:  2018-08-17       Impact factor: 2.711

9.  Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies.

Authors:  Felix Mahfoud; Michel Azizi; Sebastian Ewen; Atul Pathak; Christian Ukena; Peter J Blankestijn; Michael Böhm; Michel Burnier; Gilles Chatellier; Isabelle Durand Zaleski; Guido Grassi; Michael Joner; David E Kandzari; Ajay Kirtane; Sverre E Kjeldsen; Melvin D Lobo; Thomas F Lüscher; John William McEvoy; Gianfranco Parati; Patrick Rossignol; Luis Ruilope; Markus P Schlaich; Atif Shahzad; Faisal Sharif; Andrew S P Sharp; Horst Sievert; Massimo Volpe; Michael A Weber; Roland E Schmieder; Costas Tsioufis; William Wijns
Journal:  Eur Heart J       Date:  2020-04-21       Impact factor: 29.983
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.